Exagen
Exagen's revenue rose 19.6% to $67 million in fiscal 2025. Its operating margin was −21.1%, up from −24.5% a year earlier. Free cash flow was −$14 million. The diluted share count rose 18.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Exagen lost money in fiscal 2025: a net loss of $20 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 99 | 62 | 36 | 22 | 32 |
| Debt incl. finance leases | 28 | 30 | 20 | 21 | 26 |
| Net debt (negative means net cash) | −72 | −32 | −16 | −1 | −6 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.3x | 0.7x | 0.9x | 2.2x | 1.5x |
| Interest coverage | −9.2x | −18.8x | −9.8x | −6.1x | −3.3x |
| Current ratio | 12.1x | 7.5x | 4.0x | 2.7x | 3.5x |
| Quick ratio | 12.1x | 7.5x | 4.0x | 2.7x | 3.5x |
Cash flow
Projections
Project Exagen's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Exagen says to expect
- Full year 2026: revenue
The company reiterated full-year 2026 revenue guidance of $72 million to $75 million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Exagen shares on the open market, and 2 insiders sold $252,640.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Jeffrey G. BlackChief Financial Officer | Sold | 20,614 | $7.22 | $148,833 | Form 4 |
| Mar 3, 2026 | John AballiPresident and CEO, Director | Sold | 15,698 | $3.62 | $56,827 | Form 4 |
| Feb 24, 2026 | John AballiPresident and CEO, Director | Sold | 11,430 | $3.61 | $41,262 | Form 4 |
| Feb 24, 2026 | Jeffrey G. BlackChief Financial Officer | Sold | 1,584 | $3.61 | $5,718 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 4 of 9 | 3 of 9 |
| Rule of 40 | −13.8% | −18.9% | −1.8% |
| Altman Z'' | −13.84 | −19.87 | −14.91 |
| Accruals ratio | −12.9% | −3.6% | −12.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 5 of 9 | 4 of 9 | 3 of 9 |
Compare
Put Exagen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Exagen | FY25 | 19.6% | −21.1% | −21.4% | −115.0% | — | 3 | |
| Biodesix | FY25 | 24.1% | −31.5% | −26.6% | −69.7% | — | 3 | Compare |
| MDxHealth | FY25 | 19.8% | −13.4% | −3.1% | −41.8% | — | 3 | Compare |
| Ridgetech | FY26 | 10.2% | −1.4% | −1.1% | — | — | — | Compare |
| Cryo Cell International | FY25 | −1.3% | 1.5% | 16.6% | — | 3.5x | 6 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 32 | 40 | 42 | 48 | 46 | 52 | 56 | 67 |
| Revenue growth | — | 24.5% | 3.9% | 15.1% | −5.7% | 15.3% | 5.9% | 19.6% |
| Gross profit | 17 | 22 | 25 | 28 | 21 | 30 | 33 | 39 |
| Research and development | 2 | 2 | 4 | 7 | 10 | 5 | 5 | 6 |
| Operating income | −5 | −9 | −15 | −24 | −46 | −23 | −14 | −14 |
| Net income | −8 | −12 | −17 | −27 | −47 | −24 | −15 | −20 |
| Diluted EPS (US$) | −293.34 | −8.46 | −1.32 | −1.68 | −2.77 | −1.34 | −0.83 | −0.93 |
| Diluted shares (millions) | 0 | 4 | 13 | 16 | 17 | 18 | 18 | 22 |
| Cash flow | ||||||||
| Cash from operations | −9 | −10 | −14 | −20 | −32 | −14 | −13 | −14 |
| Capital expenditure | 0 | 0 | 0 | 2 | 4 | 1 | 0 | 1 |
| Free cash flow | −10 | −10 | −15 | −23 | −36 | −15 | −14 | −14 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 3 | 5 | 5 | 4 | 2 | 2 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 13 | 72 | 57 | 99 | 62 | 36 | 22 | 32 |
| Debt incl. finance leases | 25 | 26 | 27 | 28 | 30 | 20 | 21 | 26 |
| Total assets | 29 | 88 | 78 | 123 | 86 | 57 | 45 | 58 |
| Total liabilities | 36 | 33 | 36 | 38 | 44 | 34 | 35 | 41 |
| Shareholders' equity | −112 | 56 | 42 | 85 | 42 | 23 | 10 | 17 |
| Margins and ratios | ||||||||
| Gross margin | 52.6% | 53.4% | 60.5% | 57.4% | 46.9% | 56.1% | 59.5% | 58.3% |
| Operating margin | −15.0% | −23.0% | −36.2% | −49.8% | −101.1% | −43.5% | −24.5% | −21.1% |
| Net margin | −24.7% | −29.8% | −39.8% | −55.6% | −104.0% | −45.1% | −27.2% | −30.0% |
| Free cash flow margin | −29.3% | −25.0% | −34.6% | −46.9% | −80.0% | −29.1% | −24.8% | −21.4% |
| Rule of 40 (growth + FCF margin) | — | −0.6% | −30.7% | −31.8% | −85.7% | −13.8% | −18.9% | −1.8% |
| Return on capital | — | — | −117.2% | −158.3% | −308.9% | −210.7% | −147.1% | −115.0% |
| Return on equity | — | — | −34.2% | −42.4% | −74.4% | −72.7% | −93.8% | −147.8% |
| Return on assets | — | −20.5% | −20.0% | −26.6% | −45.2% | −33.1% | −29.7% | −38.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |